PURPOSE: To evaluate the effect of vicriviroc (VCV) on peripheral neuropathy (PN), the most prevalent neurological complication of HIV infection in HIV-1-infected treatment- experienced population. METHOD: A5211 is a randomized placebo- controlled trial evaluating VCV in treatment-experienced HIV participants failing current therapy. Participants were randomized to VCV (5, 10, or 15 mg) or placebo with optimized ritonavir-containing antiretroviral therapy and followed for 48 weeks. PN was defined as having at least mild loss of vibration bilaterally or ankle reflexes absent or hypoactive bilaterally. We estimated the association between VCV (pooled doses) with PN using a logistic generalized estimating equation. Additional outcomes included symptomatic neuropathy (SPN), painful neuropathy (PPN), and neuropathic signs and symptoms. RESULTS:118 participants (92% male, 65% white, median age of 46 years, median baseline CD4 139, median HIV-1 RNA 4.58 log) were randomized (90 on VCV and 28 onplacebo). VCV therapy did not result in a statistically significant difference relative to placebo in PN (OR = 1.52; P = .39; 95% CI 0.59, 3.90) after controlling for baseline PN status and baseline neurotoxic nucleoside reverse transcriptase inhibitor(s) use. CONCLUSION: Treatment with VCV over 48 weeks failed to result in statistically significant effect on PN in treatment-experienced participants with HIV infection relative to placebo, however potentially important effects cannot be ruled out.
RCT Entities:
PURPOSE: To evaluate the effect of vicriviroc (VCV) on peripheral neuropathy (PN), the most prevalent neurological complication of HIV infection in HIV-1-infected treatment- experienced population. METHOD: A5211 is a randomized placebo- controlled trial evaluating VCV in treatment-experienced HIVparticipants failing current therapy. Participants were randomized to VCV (5, 10, or 15 mg) or placebo with optimized ritonavir-containing antiretroviral therapy and followed for 48 weeks. PN was defined as having at least mild loss of vibration bilaterally or ankle reflexes absent or hypoactive bilaterally. We estimated the association between VCV (pooled doses) with PN using a logistic generalized estimating equation. Additional outcomes included symptomatic neuropathy (SPN), painful neuropathy (PPN), and neuropathic signs and symptoms. RESULTS: 118 participants (92% male, 65% white, median age of 46 years, median baseline CD4 139, median HIV-1 RNA 4.58 log) were randomized (90 on VCV and 28 on placebo). VCV therapy did not result in a statistically significant difference relative to placebo in PN (OR = 1.52; P = .39; 95% CI 0.59, 3.90) after controlling for baseline PN status and baseline neurotoxicnucleoside reverse transcriptase inhibitor(s) use. CONCLUSION: Treatment with VCV over 48 weeks failed to result in statistically significant effect on PN in treatment-experienced participants with HIV infection relative to placebo, however potentially important effects cannot be ruled out.
Authors: Gareth Jones; Yu Zhu; Claudia Silva; Shigeki Tsutsui; Carlos A Pardo; Oliver T Keppler; Justin C McArthur; Christopher Power Journal: Virology Date: 2005-04-10 Impact factor: 3.616
Authors: Katherine A Thompson; Melissa J Churchill; Paul R Gorry; Jasminka Sterjovski; Robert B Oelrichs; Steven L Wesselingh; Catriona A McLean Journal: Ann Neurol Date: 2004-12 Impact factor: 10.422
Authors: Roy M Gulick; Zhaohui Su; Charles Flexner; Michael D Hughes; Paul R Skolnik; Timothy J Wilkin; Robert Gross; Amy Krambrink; Eoin Coakley; Wayne L Greaves; Andrew Zolopa; Richard Reichman; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes Journal: J Infect Dis Date: 2007-06-05 Impact factor: 5.226
Authors: Sanjay C Keswani; Michelle Polley; Carlos A Pardo; John W Griffin; Justin C McArthur; Ahmet Hoke Journal: Ann Neurol Date: 2003-09 Impact factor: 10.422